🇺🇸 FDA

Company profile · Sponsor

Nurix

Nurix Therapeutics

NRIX · NYSE pharma BRISBANE, CA, USA
Pipeline
9
Drugs
0
Patents
8

Quick answer

Nurix (NRIX) is a pharma company. headquartered in BRISBANE, CA, USA. listed on NYSE. NovaPharmaNews links 9 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker NRIX
Exchange NYSE
Company type pharma
Headquarters BRISBANE, CA, USA
SEC CIK 0001549595

Pipeline (9)

Search pipeline →

  1. NX-5948

    Nurix

    B-cell Lymphoma

    phase 3 small molecule active

    2 trials

  2. NX-5948

    Nurix

    Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

    phase 2 small molecule active

    1 trial

  3. NX-5948

    Nurix

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule active

    2 trials

  4. A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

    Nurix

    Relapsed/Refractory B-cell Malignancies

    phase 1 other active

    1 trial

  5. Drug Product De-TIL-0255

    Nurix

    Platinum-resistant Ovarian Cancer

    phase 1 mab terminated

    1 trial

  6. IP

    Nurix

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  7. NX-1607

    Nurix

    Ovarian Cancer, Epithelial

    phase 1 small molecule active

    1 trial

  8. NX-2127

    Nurix

    Chronic Lymphocytic Leukemia (CLL)

    phase 1 small molecule active

    1 trial

  9. NX-5948

    Nurix

    Healthy Volunteer

    phase 1 small molecule active

    2 trials

Patents (8)

Search patents →

  1. US 12377106

    Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12234230

    Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12121540

    CBL inhibitors and compositions for use in adoptive cell therapy

    Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12091426

    Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12049471

    Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12016860

    Combination therapies with Cbl-b inhibitor compounds

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11951133

    3-substituted piperidine compounds for Cbl-b inhibition, and use thereof

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11866442

    Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Nurix?

Nurix (NRIX) is a pharma company. headquartered in BRISBANE, CA, USA. listed on NYSE. NovaPharmaNews links 9 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Nurix sponsor?

We track 9 ClinicalTrials.gov-linked programs for Nurix, including NX-5948 and 8 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Nurix company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.